



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Brioni, et al.

Serial No.: 09/985,974

Filed: November 7, 2001

Title: THE USE OF SELECTIVE  
DOPAMINE D4 RECEPTOR AGONISTS  
FOR TREATING SEXUAL  
DYSFUNCTION

Case No.: 6753.US.02

Commissioner for Patents  
Washington D.C. 20231

Group Art No.: 1614

Examiner: Bahar, M.

I hereby certify that this paper (along with any paper referred to as  
being attached or enclosed) is being deposited with the United States  
Postal Service on the date shown below with sufficient postage as  
first class mail in an envelope addressed to the:  
Commissioner for Patents  
Washington, D.C. 20231, on:

Date of Deposit: September 11, 2002

Tanya M. Parent 9/11/02  
Tanya M. Parent Date

1614  
PATENTS  
RECEIVED  
SEP 17 2002  
TECH CENTER

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled THE USE OF  
SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATING SEXUAL  
DYSFUNCTION are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. Copy of the International Search Report for PCT/US01/43139
4. References as cited on PTO 1449 (5 references); and
5. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required  
under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated  
with this communication for which full payment had not been tendered, to Deposit Account No. 01-  
0025.



23492

ABBOTT LABORATORIES  
Telephone: (847) 938-3490  
Facsimile: (847) 938-2623

Respectfully submitted,  
M. R. Schrimpf, et al.

Michael J. Ward  
Michael J. Ward  
Registration No. 37,960  
Attorney for Applicants

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Brioni, et al.

Serial No.: 09/985,974

Filed: November 7, 2001

Title: THE USE OF SELECTIVE  
DOPAMINE D4 RECEPTOR AGONISTS  
FOR TREATING SEXUAL  
DYSFUNCTION

Case No.: 6753.US.02



Group Art No.: 1614.

Examiner: Bahar, M.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents  
Washington, D.C. 20231, on:

Date of Deposit: September 11, 2002

Tanya M. Parent 9/11/02  
Tanya M. Parent Date

RECEIVED  
SEP 17 2002  
TECH CENT  
SEP 13 2002

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in 37 C.F.R. §1.97(b) but to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance. Under the provisions of 37 C.F.R. §1.97(c), this Information Disclosure Statement is accompanied by a statement as specified by 37 C.F.R. §1.97(e). Applicant respectfully petitions and requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

Documents listed in this Information Disclosure Statement were first cited in a communication from a Foreign Patent Office by the European Patent Office, in a counterpart international PCT application. This Information Disclosure Statement is being filed within three month of the mailing date of that communication. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered. A duplicate of this sheet is enclosed.



23492

ABBOTT LABORATORIES

Telephone: (847) 938-3490

Facsimile: (847) 938-2623

Respectfully submitted,  
Brioni, et al

A handwritten signature in black ink, appearing to read "Michael J. Ward".

---

Michael J. Ward

Registration No. 37,960

Attorney for Applicants

DATE: September 11, 2002 SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6753.US.02

SERIAL NO.

09/985,974

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT(S)

J. D. Brioni, et al.

FILING DATE

November 7, 2001

GROUP

1617

(Use several sheets if necessary)

(37 CFR 1.98 (b))

TECH CENTER 1600/2900

SEP 17 2002

RECEIVED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
A1	5,945,117	08/31/99	El-Rashidy et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
B1	96/04250	15.02.96	WO			
B2	00/35457	22.06.00	WO			
B3	0 982 030	01.03.00	EP			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CI	Zaleska et al., "Apomorphine in treatment of Parkinson's disease with fluctuation", Database accessio no. nlm1071032 XP002204675 Neurologia I Neurochirurgia Polska 33(6):1297-1303 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and  
not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)